This is a working overview of Preclinical research, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-28. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
1993/354) Council Tax (Alteration of Lists and Appeals) (Scotland) Regulations 1993 (S.I. 1993/355) Poultry Laying Flocks (Testing and Registration etc.) (Revocation) Order 1993 (S.I. 1993/357) A249 Trunk Road (M2 to Bobbing Improvement) Order 1993 (S.I. 1993/360) A249 Trunk Road (M2 to Bobbing Improvement Slip Roads) Order 1993 (S.I. 1993/361) A249 Trunk Road (M2 to Bobbing Improvement Detrunking) Order 1993 (S.I. 1993/362) M66 Motorway (Manchester Outer Ring Road, Denton to Middleton Section) A663 Broadway All-Purpose Connecting Road Order 1993 (S.I. 1993/363) M66 Motorway (Manchester Outer Ring Road, Denton to Middleton Section) and Connecting Roads Scheme 1988 Amendment Scheme 1993 (S.I. 1993/364) Local Government Act 1988 (Defined Activities) (Exemption) (Greater Manchester Fire and Civil Defence Authority) Order 1993 (S.I. 1993/365) Local Government Superannuation (Amendment) Regulations 1993 (S.I. 1993/366) Probation (Amendment) Rules 1993 (S.I. 1993/367) Criminal Justice Act 1991 (Contracted Out Prisons) Order 1993 (S.I. 1993/368) Scottish Hospital Trust Scheme 1993 (S.I. 1993/372) Registration of Births, Deaths and Marriages (Fees) (Amendment) Order 1993 (S.I. 1993/377) Cheshire, Lancashire and Merseyside (County Boundaries) Order 1993 (S.I. 1993/378) Norfolk and Suffolk Broads (Extension of Byelaws) Order 1993 (S.I. 1993/379) Defence Research Agency Trading Fund Order 1993 (S.I. 1993/380) Sea Fishing (Enforcement of Community Quota Measures) Order 1993 (S.I. 1993/387) Derbyshire and South Yorkshire (County and District Boundaries) Order 1993 (S.I.
=== Function in other bacteria === Many bacteria, including Escherichia coli found in the large intestine, can synthesize vitamin K2 (MK-7 up to MK-11), but not vitamin K1. In the vitamin K2 (menaquinone)–synthesizing bacteria, menaquinone transfers two electrons between two different small molecules during oxygen-independent metabolic energy production processes (anaerobic respiration). For example, a small molecule with an excess of electrons (also called an electron donor) such as lactate, formate, or NADH, with the help of an enzyme, passes two electrons to menaquinone. The menaquinone, with the help of another enzyme, then transfers these two electrons to a suitable oxidant, such as fumarate or nitrate (also called an electron acceptor). Adding two electrons to fumarate or nitrate converts the molecule to succinate or nitrite plus water, respectively. Some of these reactions generate a cellular energy source, ATP, in a manner similar to eukaryotic cell aerobic respiration, except the final electron acceptor is not molecular oxygen, but fumarate or nitrate. In aerobic respiration, the final oxidant is molecular oxygen, which accepts four electrons from an electron donor such as NADH to be converted to water. E. coli, as facultative anaerobes, can carry out both aerobic respiration and menaquinone-mediated anaerobic respiration.
The majority of human neoantigens identified in unbiased screens display a high predicted MHC binding affinity. Minor histocompatibility antigens, a conceptually similar antigen class are also correctly identified by MHC binding algorithms. Another potential filter examines whether the mutation is expected to improve MHC binding. The nature of the central T-cell receptor-exposed residues of MHC-bound peptides is associated with peptide immunogenicity.
Early in his second tenure, Mahathir visited Japan and Indonesia to reaffirm good relations, and reignited a water dispute with Singapore. By the end of 2018, several disputes over maritime and airspace borders with Singapore had continued. Mahathir met twice with president Rodrigo Duterte in his first year in office to strengthen cooperation with the Philippines on a broad range of security, economic and political issues. Mahathir again prioritised relations with Japan and strengthened economic and defence ties with Russia. He visited Vladivostok for a meeting of the Eastern Economic Forum in late 2019, where he cast doubt on the Joint Investigation Team's findings related to the downing of Malaysia Airlines Flight 17. Mahathir called the murder charges brought to four Russians related to the flight "ridiculous", calling it "a political issue on how to accuse Russia of wrongdoing". Malaysia launched a foreign policy framework in late 2019. In response to European Union regulations phasing out palm-oil based biofuels, Mahathir discussed bringing a formal complaint to the World Trade Organization or a case to the European Court of Justice with Indonesian president Joko Widodo. Mahathir condemned the killing of Saudi journalist Jamal Khashoggi in October 2018 and the assassination of Iranian General Qasem Soleimani by the United States in 2020. Mahathir was supportive of the 2018–19 Korean peace process. He also indicated that Malaysia would re-open its embassy in North Korea, which had remained closed since the 2017 assassination of Kim Jong-nam.
Sources: en.wikipedia.org
=== In bleeding control === Tranexamic acid can be used in case of postpartum hemorrhage; it can decrease the risk of death due to bleeding by one third according to the WHO. Tentative evidence supports the use of tranexamic acid in hemoptysis. In hereditary angioedema In hereditary hemorrhagic telangiectasia: tranexamic acid has been shown to reduce the frequency of epistaxis in patients with severe and frequent nosebleed episodes from hereditary hemorrhagic telangiectasia. In hyphema: tranexamic acid is effective in reducing the risk of secondary hemorrhage outcomes in people with traumatic hyphema. In liver resection: tranexamic acid did not reduce bleeding or transfusions but did increase complications.
There are several national and international bioanalytical organisations active throughout the world. Often they are part of a bigger organisation, e.g. Bioanalytical Focus Group and Ligand Binding Assay Bioanalytical Focus Group, which are both within the American Association of Pharmaceutical Scientists (AAPS) and FABIAN, a working group of the Analytical Chemistry Section of the Royal Netherlands Chemical Society. The European Bioanalysis Forum (EBF), on the other hand, is independent of any larger society or association.
Issues facing plant breeding in the future include the lack of arable land, increasingly harsh cropping conditions and the need to maintain food security, which involves being able to provide the world population with sufficient nutrition. Crops need to be able to mature in multiple environments to allow worldwide access, which involves solving problems including drought tolerance. It has been suggested that global solutions are achievable through the process of plant breeding, with its ability to select specific genes allowing crops to perform at a level which yields the desired results. One issue facing agriculture is the loss of landraces and other local varieties which have diversity that may have useful genes for climate adaptation in the future. Conventional breeding intentionally limits phenotype plasticity within genotypes and limits variability between genotypes. Uniformity does not allow crops to adapt to climate change and other biotic stresses and abiotic stresses.
Sources: en.wikipedia.org
The Students' Union's primary role is to provide a recognised representative channel between undergraduates and the university and college authorities. In February 2009, the university announced the Students' Union-run RAG Week would "no longer form part of the university calendar". The President of the Students' Union expressed the belief that the decision was unjustified, citing the more than €20,000 raised for charities that year. RAG Week continued unofficially until 2024, when the fundraising event returned with support from the Students' Union.
== Signalling == Zinc has been recognized as a messenger, able to activate signalling pathways. Many of these pathways provide the driving force in aberrant cancer growth. They can be targeted through ZIP transporters.
On 26 November 2018, the mayor of Moscow, Sergey Sobyanin, participated in the ceremony to launch the cable car above the Moskva River. This car connects the Luzhniki sports complex with Sparrow Hills and Kosygin Street. The trip from the viewpoint on Vorobyovy Gory to Luzhniki Stadium takes only five minutes, rather than 20 minutes by car.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.